1. Which of the following is true about the evaluation of severe asthma?

• The clinical usefulness of chest radiography in the treatment of severe asthma is often low.
• Only disease management benefits from the characterisation of the inflammatory endotype.
• It is important to have confirmation of the reversible airflow restriction.
• For most patients, allergen-inhalation challenges are advised.

2. Which one best represents how severe asthma should be managed?

• Only elderly individuals who misuse short-acting beta 2 agonists (SABAs) are affected.
• A higher risk of dying from asthma is often linked to current usage of inhaled corticosteroids.
• Absence of oral corticosteroid usage increases mortality associated with asthma.
• It has been shown that using SABAs excessively increases the chance of dying from asthma.

3. Which of the following is true about COVID-19 and the treatment of severe asthma?

• The risk of severe COVID-19 does not seem to be increased by biologics for severe asthma.
• Patients with severe asthma often have a greater COVID-19 prevalence than the general population.
• Inhaled corticosteroids may be linked to additional comorbidities in people with severe asthma and COVID-19.
• Biologics for all but the most severe cases of asthma should be temporarily stopped in locations where COVID-19 is prevalent.

4. Which factor should be taken into account while managing severe asthma during pregnancy?

• Exacerbations of asthma during pregnancy are uncommon.
• In all except the most extreme circumstances, inhaled corticosteroids should be stopped.
• Throughout the pregnancy, asthma management should be evaluated every four to six weeks.
• Every 1-3 months, pregnant individuals should get an asthma evaluation.

5. Which statement regarding severe asthma treatment is most accurate?

• In individuals with severe, uncontrolled asthma, macrolide medication should be avoided.
• When starting anti-IgE medication, measuring blood eosinophil levels has minimal predictive utility.
• Only individuals with severe eosinophilic asthma benefit from anti-interleukin 5 and anti-interleukin 5 receptor alpha treatments' reduction in hospitalisations.
• The usage of as-needed SABAs may be decreased in individuals with uncontrolled severe asthma by the addition of a long-acting muscarinic drug.